This interview with a top thought leader from McGill University in Canada educates clinicians on important innovations in the field of blood-based neurology biomarkers. Read now to find out how the clinical application of a biomarker test for neurofilament light chain (NfL) can help fulfil unmet needs in the management of relapsing multiple sclerosis.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


